Xpro India Q2 FY27: consolidated PAT +45% YoY to Rs7.2 Cr; UAE unit's losses cap NPM gains
PAT +44.66% YoY · revenue +47.36% · margins expanding
₹176.69 Cr
+47.36% YoY
₹7.19 Cr
+44.66% YoY
3.98%
0pp YoY
₹3.22
On a consolidated basis (primary), Xpro India's revenue from operations rose 47.4% YoY to Rs176.69 Cr (Rs119.91 Cr a year ago) and PAT (pre-minority) grew 44.7% YoY to Rs7.19 Cr (Rs4.97 Cr), with EPS at Rs3.22 against Rs2.14 YoY. Sequentially the move was muted — revenue was up just 1.3% QoQ and PAT fell 5.7% QoQ from Rs7.63 Cr in Q1 FY27 — a normal pause after Q1's sharp ramp rather than a reversal. Standalone PAT came in higher at Rs9.52 Cr on revenue of Rs176.69 Cr, with the roughly Rs2.3 Cr standalone-consolidated gap explained almost entirely by the UAE subsidiary, Xpro Dielectric Films FZ-LLC, which stayed pre-revenue and posted a Rs2.39 Cr net loss for the quarter (Rs4.49 Cr for H1) per the auditor's review note on the unreviewed-by-primary-auditor subsidiary.
Q2 FY-2027 vs prior quarters
Operating margin (PBT + finance cost + depreciation - other income, over revenue) expanded to 8.41% from 6.11% a year ago on the India business's volume-led operating leverage, but eased from 9.08% in Q1 FY27. Net profit margin was flat YoY at 3.98% versus 4.01%, and down from 4.28% in Q1 — the OPM gains were absorbed by higher depreciation (Rs5.16 Cr vs Rs2.98 Cr YoY, reflecting the new Barjora line) and a swing in foreign-exchange treatment: the quarter booked a net forex expense of ~Rs1.24 Cr versus a ~Rs0.90 Cr net forex gain in Q1, a roughly Rs2.1 Cr swing that alone accounts for most of the sequential PBT decline (PBT fell Rs1.10 Cr QoQ to Rs10.46 Cr).
The stock went into the print at ₹994.5, down 12.3% over the past month of trading.
Management is optimistic about the ramp-up of the new dielectric film line at Barjora, expecting at least 50% utilization in the current year and full capacity utilization for two Indian lines in FY27-28. The UAE line is projected for commercial production by Q3 of the current year, with excess of 50% utilization in FY
— This quarter: met
Against management's May 2026 concall guidance — at least 50% Barjora utilization in FY27 and UAE commercial production by Q3 of the current year, both framed with an optimistic, confident tone — this quarter's 47% YoY revenue growth is consistent with the ramp-up trajectory, though the UAE line's continued nil-revenue status means the Q3 FY27 commercial-production milestone is still pending, not yet met; we mark guidance as on-track rather than conclusively hit. The Board also approved a corporate guarantee of up to AED 83 million (~Rs215 Cr) to Emirates Development Bank to refinance XDF's existing AED 63 million Euro-denominated facility and fund an AED 20 million cash credit line — directly tied to funding the UAE capacity the company has guided toward. Separately, Xpro won 3 ELCINA Awards for Excellence in late September 2026, an industry-recognition data point alongside the numbers. No standalone analyst coverage exists for the stock (zero sell-side estimates found), so vsStreet could not be assessed, and no management press release or MD&A commentary accompanied this filing to independently corroborate drivers beyond the statutory notes.
W1
UAE line (XDF) commercial production — management guided Q3 of the current year (i.e. Q3 FY27); still nil revenue as of Q2
W2
Barjora dielectric film line utilization — management guided at least 50% for FY27; track via India revenue growth in coming quarters
W3
Forex/finance-cost volatility — ~Rs2.1 Cr QoQ swing in net forex expense this quarter; watch whether it normalizes or recurs
Standalone total income is printed as INR 13148.86 Lacs in the source table, but revenue+other income (18148.86) and PBT=totalIncome-totalExpenses (1279.07) both confirm it is a filing typo for 18148.86 — corrected here. Consolidated 'profit for the period' (719.06 Lacs) is pre-NCI; owners' share is 754.88 Lacs (EPS base), NCI -35.82 Lacs. UAE subsidiary XDF remains pre-revenue with a Rs 238.78 Lacs net loss this quarter, explaining most of the standalone-vs-consolidated PAT gap.
New Capacity, Compressed Margins — The Long Ramp Ahead
Revenue surged 47% year-over-year, but profit fell quarter-over-quarter as the Barjora dielectric film line ramps up. Management has extended the margin recovery timeline to 1–2 years, signaling near-term pressure ahead.
₹176.7 Cr
+47.4% YoY, +1.3% QoQ
₹7.2 Cr
+44.7% YoY, –5.7% QoQ
4.0%
down from ~5–6% prior
The headline looks strong — ₹176.7 crore in quarterly revenue, up 47% year-over-year. But flip to the bottom line and the real story emerges. Net profit fell 5.7% quarter-over-quarter to ₹7.2 crore, even as the top line grew 1.3% sequentially. That inversion — growth at the top, contraction at the bottom — is the defining signal of Q2: new capacity is being built, not yet generating returns.
Why the margin compressed
The Barjora dielectric film line, commissioned in March 2026, is in early ramp. Management reported 35% quarter-over-quarter production growth on the new line — solid progress, but still only ramping. The costs of bringing this capacity online — depreciation (heavy capex of ₹64.3 crore in H1 alone), operating costs at partial utilization, freight and shipping volatility, and most critically, competitive pricing pressure — are hitting margins in real time. Management acknowledged it: 'Operating costs, depreciation, and finance costs of the new capacity continue to weigh on profitability.' The segment that should drive premium returns, dielectric films, grew 64% year-over-year, but pricing power eroded as new competitors entered the space. Exports nearly doubled (₹17.1 crore H1, +82% year-over-year), a win, but at lower margins. The result: net margin compressed to 4.0% in Q2 from the prior run-rate of 5–6%.
What changed on this call
Three key timeline revisions signal management is taking a longer view on execution. First, Barjora utilization: In prior guidance (FY26 call), the company guided for 50% utilization in FY26. Current guidance is 70–80% utilization by Q4 FY27 — a three-quarter extension. Second, UAE timeline: The third dielectric line in the UAE was supposed to reach commercial production by Q3 FY27 (Oct–Dec 2026). Management now expects dry runs in late December 2026 or January 2027, with commercial production likely in Q1 FY28 — a 3–6 month slip. Third, margin recovery: Rather than near-term accretion, the company repositioned the 25% consolidated margin target as a 1–2 year multi-year journey (FY28–29). In each case, the message is the same: this is a multi-year ramp, not a near-term accretion story.
Revenue growth (47% YoY) materially ahead of market
Dielectric film exports doubled H1 (+82% YoY); customer momentum strong
New Barjora line commissioned on time (March 2026); producing
Long-term margin recovery path (25% target) credible via capacity + mix
Market tailwind (EV, renewable energy) durable
Margin compression (-5.7% QoQ PAT) despite revenue beat signals near-term pain
Pricing power weak; new competitors entering; management evasive on Q4 guidance
Barjora ramp at only 35% Q-o-Q; needs 2–3x to hit Q4 target
UAE timeline slipped 3–6 months (Q3 → Q1 FY28); capex risk
Capex intensity (18% of revenue) will pressure returns for 2–3 years
Margin compression near-term (PAT -5.7% QoQ despite revenue growth)
HighNew line operating costs + pricing pressure are eroding returns. If compression extends into Q4 FY27, margin recovery timeline shifts further out.
Capacity utilization miss (target 70–80% Q4, currently 35% Q-o-Q ramp)
HighRequires 2–3x monthly growth in 2 quarters. Miss would signal demand or pricing headwinds, delaying recovery path by 1–2 quarters or more.
Pricing power erosion (new competitors, management evasion on Q4 guidance)
MediumDielectric films are high-margin (35–55% EBITDA), but competitive entry is real. If pricing falls below modal ₹470–480/kg, margin recovery timeline extends.
UAE timeline slip (Q3 FY27 → Q1 FY28, 3–6 months)
MediumDelays capex payoff and FY28 earnings accretion. Each quarter of slip costs material potential revenue and extends cash flow strain.
Raw material volatility (PP prices ±20–30% per quarter; pass-through lagged)
MediumIf polymer prices rebound and pass-through lags further, margin mix will deteriorate. Management has no hedging program disclosed.
How the street is positioned
Stock price
₹1101.7 (Nov 9, 2026)
Neutral trend. Down 34.3% from all-time high ₹1677, up 39.8% from 52-week low ₹788. Trading below SMA200 (₹1121) and SMA50 (₹1135). RSI 53.4 (neutral). In drawdown, not making new highs.
FII/DII flows
FII 13.81% (−0.08pp QoQ), DII 2.94% (+0.06pp QoQ)
Flat. No major institutional repricing post-result. FII trimmed slightly; DII flat. Suggests market waiting for Q4 utilization + margin recovery proof.
Insider activity
Ashish Kacholia sold ₹2.22 Cr @ ₹970.11 (Oct 19, 2026)
Insider sold near 52-week lows, NOT near highs. This was before the Q2 result, suggesting either accumulation opportunity at lower levels or transaction unrelated to quarter outlook. Contrarian signal for patient investors.
1 · Q4 FY27 capacity utilization ramp
Management targets 70–80% utilization (900 MT) on Barjora by Q4. If achieved, sets up FY28 earnings recovery and validates multi-year thesis. If stuck at 35–50%, margin recovery timeline extends by 1–2 quarters and demand/pricing headwinds are real.
2 · UAE dry-run success (Dec 2026–Jan 2027)
Current guidance: dry runs Dec–Jan, commercial production Q1 FY28. Any further delays extend capex payoff. Any acceleration would re-rate upside. Timeline visibility is critical for investor confidence.
3 · Pricing hold on dielectric films (Q4 FY27)
Management dodged Q4 price guidance, saying 'the world is volatile.' Modal price ₹470–480/kg for standard 3.5-micron dielectric is the level to watch. If pricing compresses further (new entrants, demand slack), margin recovery timeline extends significantly.
This is a steady execution story, not a step-change. XPRO is building the right capacity (high-margin dielectric films) in the right markets (exports +82% H1). But the timeline is now clearly multi-year, not quarters. Management extended the Barjora ramp (from FY26 to Q4 FY27), delayed UAE (Q3 to Q1 FY28), and repositioned margin recovery to 1–2 years out. Near-term (Q4 FY27–Q1 FY28) will be noisy: utilization ramps, pricing holds or softens, capex continues. Long-term (FY28–29) is more credible: if the new capacity absorbs and product mix shifts to premium dielectric films, the 25% consolidated margin target is plausible.
The number to track: Barjora line utilization as a % of nameplate 4,000 MT. If tracking toward 70–80% by Q4, the multi-year thesis holds and a FY28 rerating is possible. If stuck at 35–50%, demand or pricing headwinds are real and recovery timeline extends.
Rating: Hold. Conviction on long-term execution (capacity, product mix, market tailwind) is credible. But near-term (next 2–3 quarters) will require proof — utilization ramp and pricing stability. Insider selling at lows (₹970) is a contrarian signal for patient investors, but the stock needs Q4 results and Q1 FY28 updates before a rerate higher. For now, steady execution on a multi-year timeline: hold, don't chase.
Strong topline, margin squeeze; capex ramp ahead
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Operational milestones (35% new line ramp, exports doubling) hit. Margin guidance vague; prior capacity timelines softened (UAE Q3 → Q4+). No FY27 numeric guide withdrawn.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong 47% revenue growth and dielectric film export momentum driven by new Barjora capacity, but Q2 PAT fell -5.7% QoQ as margin compressed to 4% NPM. Management credibly backs multi-year ramp (25% target in 1–2 years) via product mix and capex payoff, but near-term pricing power is weak and UAE commissioning slipped to Dec–Jan. Conviction on execution, not near-term accretion.
₹176.7 Cr
Revenue · +47.4% YoY₹7.2 Cr
Reported PAT · +44.7% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Dielectric film exports nearly doubled YoY
METH1 total exports ₹17.09 Cr vs ₹9.39 Cr, +82% YoY; dielectric films segment noted as key growth driver
Barjora new line production grew 35% vs prior quarter
METManagement stated Q2 production grew 35% over Q1 on new line
Expected to exceed ₹700 Cr revenue if market sustains
METH1 at ₹351.11 Cr annualizes ~₹700 Cr; contingent forecast, no formal FY27 target
80% utilization in Q4 = ~900 MT from new line
METAnalyst confirmed 80% capacity = 900 MT; nameplate 4 MT (all-in), line designed 2–5 micron
Margin recovery path: 25% consolidated margin 1–2 years
METQ2 NPM 4%, down -5.7% QoQ; target stated as 1–2 year trajectory, not quantified year/quarter
Earnings quality
What changed since the last call
Barjora utilization Q4 target softened
DowngradePrior FY26 call: 50% utilization in FY26; current: 70–80% in Q4 FY27 (timeline extended). Operational (proving stage 1), but margin recovery delayed.
UAE commissioning pushed back
DowngradePrior: Q3 FY27 commercial production. Current: Dry runs Dec–Jan, commercial likely Q1 FY28. 3–6 month slip acknowledged but not numeric revenue impact given.
Dielectric film export growth reaffirmed
NeutralExports H1 +82% YoY (₹17.1 Cr); management 'confident' on continued growth. No change in guidance, but trajectory strong.
Margin recovery moved to 1–2 year plan
NeutralDropped prior narrative of near-term margin accretion; now 25% consolidated target positioned as multi-year (FY28–29).
The Q&A
Analysts pressed hard on near-term margins, competitive entry in dielectric films, capex affordability, and Q4 pricing. Management held firm on moat (technical spec, customer quals, product development) but hedged on near-term price guidance and capex raise, signaling caution on macro and visibility.
EBITDA & margin guidance — Debarshi Dev, Ashya Holdings
PartialCo-extruded 5–7% EBITDA range, expected to sustain. Dielectric films EBITDA 35–55%+ (varies by thickness). No specific margin target for new line yet; citing production convenience constraints.
New line ramp and second line — Debarshi Dev, Ashya Holdings
PartialBarjora Line 2 commissioned, started Q2 production (35% Q-o-Q growth on main line). Production per line not disclosed; guided 80% utilization by Q4 for all lines combined.
Raw material cost pass-through — Tej Patel, Niveshaay Investment Advisors
AnsweredYes, taking price increases, but pass-through not full yet. Expecting nominal price increases coming through; pricing dynamic, flexible to retain market share. Freight & shipping volatility ongoing.
UAE facility timeline — Tej Patel, Niveshaay Investment Advisors
DodgedSome elements commissioned; main equipment installation by Germans ongoing. Dry runs expected late Dec or Jan; software/checkup team on schedule. Flights into Dubai disrupted but project on track (per management's framing).
Hazy film demand and competition — Tej Patel, Niveshaay Investment Advisors
AnsweredAlready supplying old lines with hazy films; new line incremental. Market growing, competition expected, but moat is technical expertise and long qualification cycles. Already gained share in hazy segment.
Raw material pricing & Borouge PPR — Purva Jhaveri, Ionic Wealth
AnsweredBuy from Borouge and others; specialty grades focus. PP prices cyclic; will take further increases if raw material persists. Indication from Borouge mixed (up then down); expect more price increases if polymer stays volatile.
Sub-3-micron film demand — Purva Jhaveri, Ionic Wealth
PartialYes, ongoing development on product and market. Not willing to comment on metallizing specifically; strategy ongoing, consistency maintained on direction.
Margin recovery timeline — Vishal Prasad, Rajmahal Capital
PartialQ4 FY27 target 80% utilization (as per prior). Margin on new line positive in last month (stage 1). Journey to 25% is 1–2 years; volume ramp + value ramp both needed. Not committing on specific quarter; two paths: volume ramp, then value ramp.
Capex affordability and equity raise — Vishal Prasad, Rajmahal Capital
AnsweredNo equity raise anticipated for system itself. Could fund subsidiary, but then would co-invest. Subsidiary may raise, but co-investor at same shareholding pattern today. No dilution planned.
Lines 4 & 5 timeline — Vishal Prasad, Rajmahal Capital
PartialYes, internal work in progress. Hear update next year. Manufacturing commissioning takes 2 years; not imminent.
Nameplate capacity and thickness spectrum — Vishal Prasad, Rajmahal Capital
AnsweredDesigned as 2-to-5-micron line. Thinner films (2-micron) lower output % vs thicker. Production mix will optimize per demand.
80% utilization = volume & export mix — Anand Kumar, Dhairya Investments
PartialMajority to domestic market. Focus on Middle East exports for freight advantage; ultra-thin will come from line. Product mix per convenience.
Chinese competition (JDL, Ningbo) — Anand Kumar, Dhairya Investments
AnsweredExporting so already competing vs Chinese. On strong footing in India and abroad; market growing, capacity expanding everywhere. Technical execution key.
Q4 pricing guidance — Anand Kumar, Dhairya Investments
DodgedWon't commit specifically on Q4 guidance; price idea ₹480–470/kg modal, 3.5-micron >₹600/kg. Price increases expected but won't be pinned to any level (don't want to reveal hand to clients).
Guidance
FY27 revenue track to ₹700 Cr+ if market sustains
MediumH1 at ₹351.1 Cr annualizes ~₹700 Cr; contingent on new line ramp and export momentum continuing. No downside scenario given.
Q4 FY27: 70–80% utilization of Barjora line (~900 MT)
MediumPath from current ~35% ramp requires 2–3x monthly output growth in 2 quarters. Achievable if demand holds and pricing improves.
Exports track to exceed ₹700 Cr (implied FY27 export turnover)
LowH1 exports ₹17.1 Cr annualizes to ₹34 Cr; no formal export target. Growth momentum strong (+82% YoY) but ₹700 Cr figure likely refers to total revenue, not exports.
Consolidated margin recovery to 25% in 1–2 years
MediumMulti-year target; subject to capacity absorption and product mix (premium films). Current 4% NPM vs target implies 6x expansion, credible but dependent on execution and pricing.
Dielectric films: 35–55%+ EBITDA margin (varies by thickness)
HighManagement confirms this as current segment range; new line at 35% entry level, improving as spec mix shifts to ultra-thin and premium.
Co-extruded business: 5–7% EBITDA, expected to sustain
HighStated as 'expected to sustain'; implies no aggressive expansion in this segment, focus on higher-margin dielectric films.
H1 capex deployed ₹64.3 Cr; full-year capex not quantified
MediumBarjora line capex done; UAE in progress. Total capex for all lines (Barjora + UAE + Lines 4–5 R&D) not broken out. Financing via ECB credit, no equity raise needed in near term.
Lines 4 & 5: internal development ongoing; update FY28
Low2-year manufacturing timeline implied. No capex or revenue guidance; exploratory stage.
Risks the call surfaced
Margin compression near-term
HighQ2 PAT ₹7.2 Cr at 4% NPM, down -5.7% QoQ despite 1.3% QoQ revenue growth. New line operating costs, freight volatility, and competitive pricing pressure persist. Recovery path (25% by 1–2 years) vague and contingent.
Capacity utilization risk
MediumBarjora new line at only 35% Q-o-Q production growth; target is 70–80% utilization by Q4 FY27 (900 MT), implying 2–3x ramp in 2 quarters. Market demand, pricing environment, and product approvals all critical. Shortfall would extend margin recovery timeline.
UAE project timeline slip
MediumPrior guidance: UAE line commercial production by Q3 FY27 (Oct–Dec 2026). Current update: dry runs expected Dec–Jan 2026/27 (3–6 month slip). Commercial revenue unlikely before Q1 FY28. Impacts H2 FY27 cash flow and FY28 margin accretion plans.
Pricing power erosion
MediumManagement candidly acknowledged competitive pricing pressure to retain market share; new entrants (2–3) in dielectric films space; global overcapacity in polymers. Q4 pricing guidance dodged (management refused to commit). Implies weak negotiating position. Margin recovery dependent on premium product mix, not pricing leverage.
Raw material cost volatility
MediumPolymer (PP) prices volatile: up 30% Q1, down 20% Q2. Management taking price increases but pass-through incomplete and lagged. Freight/shipping costs volatile (cited as working capital headwind). Margin squeezed near-term if raw costs stay elevated or rebound.
Management
Score 6/10. Transparent on challenges (margin pressure, competition, timeline slips); candid Q&A (admits not committing on Q4 price, won't disclose per-line breakup). But evasive on specific targets (margin guidance, capex plan, export mix). On-track on capacity (Barjora line commissioned on time, producing). UAE delayed (Q3 target → Dec–Jan slip). Barjora ramp at 35% Q-o-Q (credible but below bull case). Financial delivery soft (PAT -5.7% QoQ despite revenue beat).
1 · Q4 FY27 (Jan–Mar)
Barjora line ramp-up to 70–80% utilization; pricing pass-through expected
2 · Dec 2026 – Jan 2027
UAE facility dry runs (delayed from Q3 plan); commissioning timeline tightening
3 · FY28
Full utilization of two Indian lines; UAE commercial production; margin expansion toward 15%+ range
Conviction on execution, not near-term accretion.